2. Signaling Pathways
  3. Apoptosis
    Metabolic Enzyme/Protease
  4. Glutathione Peroxidase
  5. Glutathione Peroxidase Inhibitor

Glutathione Peroxidase Inhibitor

Glutathione Peroxidase Inhibitors (31):

Cat. No. Product Name Effect Purity
  • HY-100218A
    RSL3
    		Inhibitor 99.90%
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
  • HY-100002
    ML162
    		Inhibitor 99.35%
    ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines
  • HY-138153
    JKE-1674
    		Inhibitor 98.30%
    JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors.
  • HY-B0182
    Carmofur
    		Inhibitor 99.95%
    Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
  • HY-141809
    GPX4-IN-3
    		Inhibitor 99.90%
    GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM.
  • HY-163332
    MPO-IN-6
    		Inhibitor
    MPO-IN-6 (compound ADC) is an electrophile with good antioxidant and anti-inflammatory properties. MPO-IN-6 is a myeloperoxidase (MPO), dipeptidyl peptidase-4 (DPP-4), and α-glucosidase (α-GD) inhibitor with IC50s of 10 μM, 31.02 μM, and 46.05 μM, respectively. MPO-IN-6 is a potential cardiovascular preventive agent.
  • HY-163272
    GPX4/CDK-IN-1
    		Inhibitor
    GPX4/CDK-IN-1 (Compound B9) is a dual inhibitor of GPX4 and CDK, with IC50 values of 542.5 nM, 191.2 nM and 68.1 nM for GPX4, CDK4 and CDK6, reapectively. GPX4/CDK-IN-1 shows strong cancer cell growth inhibition in vivo.
  • HY-149455
    GPX4-IN-8
    		Inhibitor
    GPX4-IN-8 (compound A80) is a potent GPX4 inhibitor. GPX4-IN-8 shows antiproliferative activity.
  • HY-N0070
    Solasonine
    		Inhibitor 99.19%
    Solasonine is a ferroptosis inducer which can be isolated from Solanum melongena that has anti-infection, anti-cancer, and neurogenesis promoting properties. Solasonine promotes ferroptosis of HCC cells via destruction of the glutathione redox system induced by inhibiting GPX4, and can be used for cancer research.
  • HY-111341
    AZD5904
    		Inhibitor 99.93%
    AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC50 of 140 nM and has similar potency in mouse and rat.
  • HY-100873
    PF-1355
    		Inhibitor 99.86%
    PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases.
  • HY-115486
    MPO-IN-28
    		Inhibitor 99.28%
    MPO-IN-28 (Compound 28) is a myeloperoxidase (MPO) inhibitor with an IC50 of 44 nM.
  • HY-N4288
    4-Methylesculetin
    		Inhibitor 98.21%
    4-Methylesculetin is an orally active natural coumarin derivative, with potent anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase activity and reduces IL-6 level.
  • HY-106228
    HLF1-11
    		Inhibitor 99.91%
    HLF1-11, a human lactoferrin-derived peptide, is a broad spectrum antimicrobial agent. HLF1-11 inhibits human MPO activity. HLF1-11 also directs GM-CSF-driven monocyte differentiation toward macrophages, and enhances immune responses.
  • HY-125039
    N-Acetyl lysyltyrosylcysteine amide
    		Inhibitor 99.81%
    N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation.
  • HY-155663
    GPX4-IN-5
    		Inhibitor 99.35%
    GPX4-IN-5 (Compound C18) is a GPX4 covalent inhibitor with an IC50 value of 0.12 μM. GPX4-IN-5 (Compound C18) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .
  • HY-145197
    MPO-IN-3
    		Inhibitor 99.73%
    MPO-IN-3 is a potent myeloperoxidase (MPO) inhibitor (WO2013068875A1, example 191). Myeloperoxidase (MPO) is a heme-containing enzyme belonging to the peroxidase superfamily.
  • HY-19321
    PF-06282999
    		Inhibitor 99.41%
    PF-06282999 is a potent and selective myeloperoxidase inhibitor which is potential useful for the treatment of cardiovascular diseases.
  • HY-139915
    MPO-IN-1
    		Inhibitor 99.02%
    MPO-IN-1 is a potent, orally active, and irreversible indole-containing inhibitor of myeloperoxidase (MPO). MPO-IN-1 has IC50s of 2.6 μM and 5.3 μM for MPO and thyroid peroxidase (TPO), respectively. MPO-IN-1 inhibits MPO activity in an acute mouse model of inflammation.
  • HY-155664
    GPX4-IN-6
    		Inhibitor
    GPX4-IN-6 (Compound C25) is a GPX4 covalent inhibitor with an IC50 value of 0.13 μM. GPX4-IN-6 (Compound C25) can induce ferroptosis for the research of triple-negative breast cancer (TNBC) .